IRIX
What one share of Iridex holds
Electromedical and Electrotherapeutic Apparatus
IRIDEX Corporation (“IRIDEX”) is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases.
Iridex’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-07-04; the balance sheet is as of 2026-07-04.
| Sales | $2.99 |
|---|---|
| Profit | −$0.21 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$0.12 |
| Cash and investments | $0.27 |
| Debt | $0.22 |
| Book value | $0.21 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $4.54 | −$1.15 | $0.10 | −$0.12 | — | $3.46 |
| 2017 | $3.60 | −$1.11 | $0.05 | −$0.36 | — | $2.63 |
| 2018 | $3.49 | −$1.05 | $0.04 | −$0.86 | — | $2.20 |
| 2019 | $3.17 | −$0.64 | $0.01 | −$0.59 | — | $1.65 |
| 2020 | $2.63 | −$0.46 | $0.01 | −$0.24 | — | $1.25 |
| 2021 | $3.50 | −$0.34 | $0.01 | $0.52 | — | $1.47 |
| 2022 | $3.57 | −$0.47 | $0.02 | −$0.62 | — | $1.08 |
| 2023 | $3.22 | −$0.59 | $0.01 | −$0.42 | — | $0.59 |
| 2024 | $2.96 | −$0.54 | $0.00 | −$0.44 | — | $0.13 |
| 2025 | $3.11 | −$0.26 | $0.01 | −$0.13 | — | $0.28 |